6 February 2018
Sofitel Legend Amsterdam The Grand
2018 Presenting Companies
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®.
The Company employs a hybrid business model where it invests directly in its own development programmes as well as collaborating with pharmaceutical partners at all stages of discovery and development. Where there are appropriate opportunities, Ablynx will retain some or all rights to commercialise its products.
Atlas Genetics (UK)
Atlas Genetics is a diagnostics company focused on ultra-rapid (≤ 30 mins) POC molecular tests for infectious diseases and genotyping. The initial commercial focus is on sexually transmitted infections, initially for chlamydia and gonorrhoea, which represents a 67 million tests per year market with well-established regulatory path and reimbursement www.atlasgenetics.com
Cardior Pharmaceuticals (GER)
Cardior is a spin-off of Hannover Medical School and dedicated to becoming the world leader in design, research and development of non-coding RNA-based therapeutics for cardiovascular diseases. Cardior aims to market its products in collaboration with a strategic pharma partner after clinical proof-of-concept data in patients with myocardial infarction and heart failure.
Curetis is a molecular diagnostics company that focuses on the development and commercialisation of reliable, fast and cost-effective products for diagnosing severe infectious diseases. To date, Curetis has raised €44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over €63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to €25 million.
eTheRNA immunotherapies is focusing on therapies that activate the immune system through a specific focus on programming dendritic cells (DC) with synthetic mRNA. Encouraged by the impressive complete response rate (>20%) of the combination therapy including TriMix-DC and ipilimumab in patients with advanced melanoma, the company is committed to establishing its TriMix technology as the gold standard in the wider area of onco-immunotherapy.
Eloxx Pharmaceuticals (ISR)
ERYtech Pharma (FRA)
Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs.
Evotec AG (GER)
Evotec is a drug discovery company focused on rapidly progressing innovative product approaches with its customers. It operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target identification to IND-enabling studies and high-end CMC (Chemistry, manufacturing and controls). The Company focuses on key therapeutic areas including neuronal diseases, diabetes and diabetic complications, oncology, pain, anti-infectives, respiratory and fibrosis.
For additional information please go to www.evotec.com.
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab’s technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com
- Spin-off of the Institut Paoli-Calmette in Marseille
- Founded by Prof. Daniel Olive, a renowned pioneer in the area of co-signalling pathways
- Developing a new generation of agonist and antagonist therapeutic antibodies with applications in immuno-oncology (novel checkpoint inhibitors) and autoimmune diseases
Immunic Therapeutics (GER)
Immunic AG is clinical stage biotech company founded in 2016 and focused on the development of immune modulators for two preclinical and clinical stage products to block Th17 and Th1-mediated immune and autoimmune responses. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors.
Kiadis Pharma (NL)
Kiadis Pharma is a clinical stage company developing therapies for patients with late stage blood cancers and non-malignant blood disorders. ATIR101™ is a cell based medicinal product manufactured from mismatched family members to allow for T-cell infusions after stem-cell transplantation to strengthen the patients immune system w/o eliciting life threatening acute severe chronic graft versus host disease.
Medigene is a publicly listed (Frankfurt: MDG1, prime standard, TecDAX) biotechnology company headquartered in Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Merus started operations in 2006 and listed on Nasdaq in May 2016. In December 2016, Merus closed a collaboration with Incyte that included $200 million upfront consideration for licence and equity. Merus discovers and develops differentiating of bispecific antibodies aimed at substantially prolonging the lives of cancer patients.
Mint Solutions/MedEye (NL)
MedEye builds tools to help nurses and doctors provide exceptional care for patients. The first product ensures that patients get the right medication at the right time, improving safety, saving lives and reducing the costs of medication errors worldwide.
Nouscom is an IO biotech, founded in 2015, with operations in Switzerland and Italy dedicated to the development of next-generation cancer vaccines. Nouscom raised €12 million from Versant Ventures and LSP. Nouscom’s founders come from Okairos, sold to GSK in 2013, where they developed a genetic vaccine platform for infectious diseases (HIV, HCV, malaria, Ebola, RSV).
Oxford Endovascular (UK)
OxThera AB (SWE)
OxThera is developing a novel treatment, Oxabact, for Primary hyperoxaluria (PH), a fatal ultra-orphan disease in children, and where there are currently no available therapies. The company has initiated a pivotal Phase III study in PH with Oxabact in order to stop and/or delay disease progression. Oxabact holds orphan drug designations in the EU and the US for the treatment of PH, and in the EU for treatment of Short Bowel Syndrome (SBS).
Simplify Medical (USA)
Simplify™ Medical is a San Francisco Bay Area-based medical device company focused on the design, development and clinical testing of the most advanced cervical artificial disc for use in the spine. Simplify Disc is composed of advanced materials, allowing for advanced imaging capability, superb kinematics and provides movement and function similar to that of intact natural discs.
Ventaleon GmbH is a biotechnology company focused on the development of inhaled treatments against viral infections. The Company’s lead therapy candidate is an inhaled form of LASAG (D,L-lysine acetylsalicylate • glycine), which it is developing to treat severe influenza. Ventaleon was founded as a spin-off from Activaero.
Vivasure Medical (IRE)
Percutaneous large (12F+) arteriotomy closure is an area of unmet clinical need which is growing rapidly, driven by the expanding penetration of procedures such as Transcatheter Aortic Valve Repair. Vivasure’s technology enables a fully percutaneous approach for these patients, yielding significant clinical and economic benefits for patients, physicians and payers.
Zealand Pharma (DEN)
Zealand Pharma A/S is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of product candidates that primarily target specialty diseases with significant unmet needs.